Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Neurobiol Aging. 2010 May;31(5):725-31. doi: 10.1016/j.neurobiolaging.2008.06.012. Epub 2008 Jul 30.
Mutations in three genes (PSEN1, PSEN2, and APP) have been identified in patients with early-onset (<65 years) Alzheimer's disease (AD). We performed a screening for mutations in the coding regions of presenilins, as well as exons 16 and 17 of the APP gene in a total of 231 patients from the Iberian peninsular with a clinical diagnosis of early-onset AD (mean age at onset of 52.9 years; range 31-64). We found three novel mutations in PSEN1, one novel mutation in PSEN2, and a novel mutation in the APP gene. Four previously described mutations in PSEN1 were also found. The same analysis was carried in 121 elderly healthy controls from the Iberian peninsular, and a set of 130 individuals from seven African populations belonging to the Centre d'Etude du Polymorphisme Humain-Human Genome Diversity Panel (CEPH-HGDP), in order to determine the extent of normal variability in these genes. Interestingly, in the latter series, we found five new non-synonymous changes in all three genes and a presenilin 2 variant (R62H) that has been previously related to AD. In some of these mutations, the pathologic consequence is uncertain and needs further investigation. To address this question we propose and use a systematic algorithm to classify the putative pathology of AD mutations.
已经在早发性(<65 岁)阿尔茨海默病(AD)患者中鉴定出三个基因(PSEN1、PSEN2 和 APP)的突变。我们在总共 231 名来自伊比利亚半岛的有早发性 AD 临床诊断的患者(发病年龄的平均值为 52.9 岁;范围 31-64)中,对早发性 AD 患者进行了编码区的 PSEN1 和 PSEN2 突变以及 APP 基因外显子 16 和 17 的筛查。我们发现了三个 PSEN1 中的新突变,一个 PSEN2 中的新突变和 APP 基因中的一个新突变。还发现了四个先前描述的 PSEN1 突变。对来自伊比利亚半岛的 121 名老年健康对照者和来自属于人类基因组多样性计划的七个非洲人群的 130 名个体(CEPH-HGDP)进行了相同的分析,以确定这些基因的正常变异程度。有趣的是,在后一系列中,我们在所有三个基因中发现了五个新的非同义变化和一个先前与 AD 相关的 PSEN2 变体(R62H)。在这些突变中的一些中,病理后果不确定,需要进一步研究。为了解决这个问题,我们提出并使用了一种系统的算法来对 AD 突变的潜在病理学进行分类。